G3BP1 interacts with YWHAZ to regulate chemoresistance and predict adjuvant chemotherapy benefit in gastric cancer

[1]  Li Jiang,et al.  Stress granule: A promising target for cancer treatment , 2019, British journal of pharmacology.

[2]  F. Veith,et al.  Why randomized controlled trials do not always reflect reality. , 2019, Journal of vascular surgery.

[3]  W. Xue,et al.  G3BP1 promotes DNA binding and activation of cGAS , 2018, Nature Immunology.

[4]  Herbert Yu,et al.  A G3BP1-Interacting lncRNA Promotes Ferroptosis and Apoptosis in Cancer via Nuclear Sequestration of p53. , 2018, Cancer research.

[5]  João Pedro de Magalhães,et al.  Gene co-expression analysis for functional classification and gene–disease predictions , 2017, Briefings Bioinform..

[6]  Quan P. Ly,et al.  Gastric Cancer, Version 3.2016; Clinical Practice Guidelines in Oncology , 2016 .

[7]  Jin-bo Gao,et al.  Molecular mechanisms of chemoresistance in gastric cancer , 2016, World journal of gastrointestinal oncology.

[8]  Shufeng Zhou,et al.  Molecular mechanisms for tumour resistance to chemotherapy , 2016, Clinical and experimental pharmacology & physiology.

[9]  K. Pilancı,et al.  Current adjuvant treatment modalities for gastric cancer: From history to the future. , 2016, World journal of gastrointestinal oncology.

[10]  Quan P. Ly,et al.  Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[11]  F. Roviello,et al.  Surgical management of advanced gastric cancer: An evolving issue. , 2016, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[12]  Yuanyuan Ruan,et al.  Overexpression of Ras‐GTPase‐activating protein SH3 domain‐binding protein 1 correlates with poor prognosis in gastric cancer patients , 2015, Histopathology.

[13]  D. Shin,et al.  Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[14]  A. Bode,et al.  Resveratrol induces apoptosis by directly targeting Ras-GTPase activating protein SH3 domain binding protein 1 (G3BP1) , 2014, Oncogene.

[15]  L. Galluzzi,et al.  Systems biology of cisplatin resistance: past, present and future , 2014, Cell Death and Disease.

[16]  Wenlin Xu,et al.  Relationship between P53 Status and Response to Chemotherapy in Patients with Gastric Cancer: A Meta-Analysis , 2014, PloS one.

[17]  H. Chun,et al.  Chemotherapy for Advanced Gastric Cancer: Review and Update of Current Practices , 2013, Gut and liver.

[18]  H. Tsuda,et al.  Overexpression of YWHAZ relates to tumor cell proliferation and malignant outcome of gastric carcinoma , 2013, British Journal of Cancer.

[19]  M. Higuchi,et al.  Stress Granules Inhibit Apoptosis by Reducing Reactive Oxygen Species Production , 2012, Molecular and Cellular Biology.

[20]  L. Varışlı.  Meta-analysis of the expression of the mitosis-related gene Fam83D. , 2012, Oncology letters.

[21]  L. Galluzzi,et al.  Molecular mechanisms of cisplatin resistance , 2012, Oncogene.

[22]  Inkyung Jung,et al.  A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. , 2012, European journal of cancer.

[23]  L. Jacks,et al.  Comparison of Gastric Cancer Survival Following R0 Resection in the United States and Korea Using an Internationally Validated Nomogram , 2010, Annals of surgery.

[24]  R. Parker,et al.  Eukaryotic stress granules: the ins and outs of translation. , 2009, Molecular cell.

[25]  C. Reynolds,et al.  Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy , 2009, Clinical Cancer Research.

[26]  Yasuo Ohashi,et al.  Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. , 2007, The New England journal of medicine.

[27]  Mihee M. Kim,et al.  Modulation of p53 and MDM2 activity by novel interaction with Ras-GAP binding proteins (G3BP) , 2007, Oncogene.

[28]  Elisabeth Brambilla,et al.  DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. , 2006, The New England journal of medicine.

[29]  C. V. D. van de Velde,et al.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.

[30]  J. Tazi,et al.  Control of Fetal Growth and Neonatal Survival by the RasGAP-Associated Endoribonuclease G3BP , 2005, Molecular and Cellular Biology.

[31]  M. Raderer,et al.  Palliative chemotherapy for advanced gastric cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  W. Sadee,et al.  Growth factor signaling and resistance to cancer chemotherapy. , 2004, Current topics in medicinal chemistry.

[33]  Fuminori Tsuruta,et al.  JNK promotes Bax translocation to mitochondria through phosphorylation of 14‐3‐3 proteins , 2004, The EMBO journal.

[34]  P. Johnston,et al.  5-Fluorouracil: mechanisms of action and clinical strategies , 2003, Nature Reviews Cancer.

[35]  K. Chébli,et al.  The RasGAP-associated endoribonuclease G3BP assembles stress granules , 2003, The Journal of cell biology.

[36]  Masashi Narita,et al.  14-3-3 Interacts Directly with and Negatively Regulates Pro-apoptotic Bax* , 2003, The Journal of Biological Chemistry.

[37]  Scott W. Lowe,et al.  Apoptosis A Link between Cancer Genetics and Chemotherapy , 2002, Cell.

[38]  J. Tazi,et al.  RasGAP-Associated Endoribonuclease G3BP: Selective RNA Degradation and Phosphorylation-Dependent Localization , 2001, Molecular and Cellular Biology.

[39]  Scott A. Hundahl,et al.  Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. , 2001, The New England journal of medicine.

[40]  L. Debussche,et al.  A Ras-GTPase-activating protein SH3-domain-binding protein , 1996, Molecular and cellular biology.